April 20, 2011 -- Morningside Ventures, the Hong Kong venture capital company, participated in the $19.25 million second round funding of Aduro BioTech of Berkeley, California. Aduro uses listeria bacteria as the basis for new vaccines, which it is developing to fight cancer and infectious diseases. Morningside’s portfolio of life science investments numbers 36 companies, including ten ventures that are headquartered or have some of their operations in China (including one in Hong Kong). More details....
